CCL2 and neoplasm: These results in animal models are strengthen by clinical studies demonstrating a negative prognostic role for increased numbers of IMs and elevated serum CCL2 concentrations in patients with various malignancies [40–43] and suppression of tumor growth in patients with bone metastases by blockade of the CCL2 receptor [44].